Circadien gene variants influence sleep and the sleep electroencephalogram in humans by Chang, A.-M. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=icbi20
Download by: [Harvard Library] Date: 04 November 2016, At: 05:03
Chronobiology International
The Journal of Biological and Medical Rhythm Research
ISSN: 0742-0528 (Print) 1525-6073 (Online) Journal homepage: http://www.tandfonline.com/loi/icbi20
Circadian gene variants influence sleep and the
sleep electroencephalogram in humans
Anne-Marie Chang, Andrew C. Bjonnes, Daniel Aeschbach, Orfeu M. Buxton,
Joshua J. Gooley, Clare Anderson, Eliza Van Reen, Sean W. Cain, Charles A.
Czeisler, Jeanne F. Duffy, Steven W. Lockley, Steven A. Shea, Frank A. J. L.
Scheer & Richa Saxena
To cite this article: Anne-Marie Chang, Andrew C. Bjonnes, Daniel Aeschbach, Orfeu M.
Buxton, Joshua J. Gooley, Clare Anderson, Eliza Van Reen, Sean W. Cain, Charles A. Czeisler,
Jeanne F. Duffy, Steven W. Lockley, Steven A. Shea, Frank A. J. L. Scheer & Richa Saxena (2016)
Circadian gene variants influence sleep and the sleep electroencephalogram in humans,
Chronobiology International, 33:5, 561-573, DOI: 10.3109/07420528.2016.1167078
To link to this article:  http://dx.doi.org/10.3109/07420528.2016.1167078
View supplementary material Published online: 18 Apr 2016.
Submit your article to this journal Article views: 270
View related articles View Crossmark data
REPORT
Circadian gene variants influence sleep and the sleep electroencephalogram in
humans
Anne-Marie Changa,b,c,d, Andrew C. Bjonnesc,e, Daniel Aeschbacha,b,f, Orfeu M. Buxtona,b,d,g, Joshua J. Gooleya,b,
Clare Andersona,b, Eliza Van Reena,b, Sean W. Caina,b, Charles A. Czeislera,b, Jeanne F. Duffya,b, Steven W. Lockleya,b,
Steven A. Sheaa,b,h, Frank A. J. L. Scheera,b*, and Richa Saxenaa,b,c,e*
aDivision of Sleep and Circadian Disorders, Department of Medicine and Department of Neurology, Brigham and Women’s Hospital,
Boston, MA, USA; bDivision of Sleep Medicine, Harvard Medical School, Boston, MA, USA; cMedical and Population Genetics, Broad
Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA; dDepartment of Biobehavioral Health, Pennsylvania
State University, University Park, PA, USA; eDepartment of Anesthesia, Critical Care and Pain Medicine and Center for Human Genetic
Research, Massachusetts General Hospital, Boston, MA, USA; fInstitute of Aerospace Medicine, German Aerospace Center, Cologne,
Germany; gDepartment of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, USA; hOregon Institute of
Occupational Health Sciences, Oregon Health & Science University, Portland, OR, USA
ABSTRACT
The sleep electroencephalogram (EEG) is highly heritable in humans and yet little is known about
the genetic basis of inter-individual differences in sleep architecture. The aim of this study was to
identify associations between candidate circadian gene variants and the polysomnogram,
recorded under highly controlled laboratory conditions during a baseline, overnight, 8 h sleep
opportunity. A candidate gene approach was employed to analyze single-nucleotide polymorph-
isms from five circadian-related genes in a two-phase analysis of 84 healthy young adults (28 F;
23.21 ± 2.97 years) of European ancestry. A common variant in Period2 (PER2) was associated with
20 min less slow-wave sleep (SWS) in carriers of the minor allele than in noncarriers, representing
a 22% reduction in SWS duration. Moreover, spectral analysis in a subset of participants (n = 37)
showed the same PER2 polymorphism was associated with reduced EEG power density in the low
delta range (0.25–1.0 Hz) during non-REM sleep and lower slow-wave activity (0.75–4.5 Hz) in the
early part of the sleep episode. These results indicate the involvement of PER2 in the homeostatic
process of sleep. Additionally, a rare variant in Melatonin Receptor 1B was associated with longer
REM sleep latency, with minor allele carriers exhibiting an average of 65 min (87%) longer latency
from sleep onset to REM sleep, compared to noncarriers. These findings suggest that circadian-
related genes can modulate sleep architecture and the sleep EEG, including specific parameters
previously implicated in the homeostatic regulation of sleep.
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Introduction
Sleep is regulated by two main physiological pro-
cesses: (1) the circadian timing system (process
C), regulating daily rhythms of sleep and wake-
fulness; and (2) the sleep homeostatic process
(process S), which tracks accumulating sleep
pressure with time awake and which decreases
with time asleep (Borbély, 1982). The prevalence
and amplitude of slow waves in the sleep electro-
encephalogram (EEG), typically quantified by
slow-wave activity (SWA; 0.75–4.5 Hz power
density) or slow-wave sleep (SWS), serve as
markers of homeostatic sleep pressure
(Achermann et al., 1993). The EEG is highly
heritable, both during wakefulness (h2 =
76–89%) (Lennox et al., 1945; van Beijsterveldt
& van Baal, 2002) and during sleep (h2 = 50–96%)
(Ambrosius et al., 2008; Landolt & Dijk, 2010;
Linkowski, 1999). Surprisingly, despite the high
heritability of EEG traits, little is known about the
genetic basis of these inter-individual differences
in the sleep EEG.
Several sleep-associated genetic variants have
been identified in human candidate-gene studies
but associations have not been consistently
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reproduced; namely in PER3, DQB1*0602, ADA,
ADORA2A, BDNF and COMT (Bachmann et al.,
2012; Bodenmann et al., 2012; Bodenmann &
Landolt, 2010; Guindalini et al., 2014; Mignot
et al., 1999; Retey et al., 2005; Viola et al., 2007).
Of these genes, however, only PER3 is considered
a genetic component of the circadian molecular
timing system shown to alter the sleep EEG in
humans (Viola et al., 2007). Gene variants in
BDNF, a circadian-related gene, have also been
implicated in changes to EEG during sleep
(Bollen & Curran, 2005; Guindalini et al., 2014).
In the current study, we used a candidate gene
approach to identify associations between single-
nucleotide polymorphisms (SNPs) in circadian-
related genes and polysomnographic (PSG) mea-
sures collected under controlled laboratory condi-
tions, an ideal setting for reducing environmental
and behavioral variation to identify genetic var-
iants with a strong effect. Common SNPs in five
circadian-related genes were genotyped in our
laboratory sample: Circadian Locomotor Output
Cycles Kaput (CLOCK), Cryptochrome2 (CRY2),
basic helix-loop-helix family, member e41
(BHLHE41; or DEC2), Period2 (PER2) and
Melatonin Receptor1B (MTNR1B). As an initial
exploration of the role of circadian genes in
sleep physiology, we selected these genes as can-
didates based on: (1) previously reported associa-
tions with sleep phenotypes in the case of
CLOCK, DEC2 and PER2 (Allebrandt et al.,
2010; He et al., 2009; Toh et al., 2001); and (2)
association with type 2 diabetes (T2D) risk
(Dupuis et al., 2010; Lyssenko et al., 2008;
Prokopenko et al., 2008), in the case of CRY2
and MTNR1B. Furthermore, MTNR1B gene var-
iants were included in this analysis because of
previously documented association with meta-
bolic measures (Dupuis et al., 2010; Lyssenko
et al., 2008; Prokopenko et al., 2008) and its
role as an output of the clock, not because of a
role in the core molecular clock. Because sleep
disturbances and short sleep duration lead to
increased risk of T2D (Nedeltcheva & Scheer,
2014; Spiegel et al., 2005), we hypothesized that
changes in sleep quality and/or duration may
provide a mechanistic link between known var-
iants in this gene and T2D risk (Hanlon & Van
Cauter, 2011).
Methods
Overview
This genetic study includes data from individuals
who previously participated in one of several
inpatient physiological protocols in which their
sleep EEG was recorded in the Intensive
Physiological Monitoring Unit of the Brigham
and Women’s Hospital. Written informed con-
sents, both for the original in-laboratory studies
and for the genetic studies, were obtained from
each study participant. The Partners Human
Research Committee approved the protocol and
study procedures conformed to the Declaration of
Helsinki.
Study participants and screening procedures
A total of 101 healthy adults aged 18–35 years (34 F;
mean age ± SD 23.10 ± 3.28 years) were enrolled in
this study. A PSG recording collected during an 8 h
baseline overnight sleep episode (first or third night;
see below; Figure 1) and genetic samples obtained
from each participant were used for association
analyses.
Prior to admission, study participants com-
pleted extensive screening procedures to ensure
eligibility. Inclusion criteria required that partici-
pants were 18–35 years of age and in good health,
free from medical or psychological conditions or
disorders. While the protocols in which the
volunteers participated varied slightly from each
other with respect to specific screening proce-
dures, all protocols included a physical examina-
tion, laboratory tests of blood and urine samples,
a 12-lead electrocardiogram (ECG), and an inter-
view with a clinical psychologist to confirm good
medical and psychological health. Exclusion cri-
teria included night work in the prior 3 years and
travel across >1 time zone in the prior 3 months.
During the 3-week pre-admission screening
interval, participants were asked to refrain from
taking medications, alcohol, caffeine and nico-
tine; and they maintained a self-selected, stable,
8 h sleep schedule each night, which was verified
with daily sleep diaries, time-stamped telephone
calls at bedtime and wake time, and wrist acti-
graphy for a minimum of 1 week prior to
admission.
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Genotyping
DNA was extracted from whole blood using
Qiagen Autopure LS (Qiagen, Limburg, The
Netherlands). A total of 116 SNPs tagging com-
mon variation and rare missense variants from the
five candidate genes (CLOCK, CRY2, BHLHE41,
PER2 and MTNR1B; ±20 kb) were selected, pro-
viding full coverage for each gene (see supplemen
tary table 1 for full list). SNPs with a minor allele
frequency (MAF) > 0.05 were selected using a
pairwise tagging threshold (r2 > 0.8) in four popu-
lations: Northern and Western European (CEU),
Yoruba African (YRI), Han Chinese (CHB) and
Japanese (JPT) in HapMap release 21 in Tagger on
Haploview (Barrett et al., 2005). Additionally, 58
African-American and Hispanic ancestry informa-
tive markers were genotyped to test and correct for
population stratification. Genotyping was per-
formed using the Sequenom platform (Broad
Institute, Cambridge, MA).
Standard quality control criteria included SNP
genotyping rate > 90%, MAF > 1% and Hardy–
Weinberg equilibrium (HWE) p > 10−6 and were
assessed using PLINK (Purcell et al., 2007). Also,
11 SNPs were excluded due to low genotyping
rate, 20 SNPs were excluded due to low MAF
and 3 SNPs were excluded on the basis of depar-
ture from HWE; several of the SNPs were excluded
by more than one criterion leaving 87 SNPs that
passed all quality control filters. For primary asso-
ciation analysis, 84/101 participants that were
genetically categorized as being of European
ancestry (within 4 SD of the HapMap release 3
CEU panel based on principal components analy-
sis) were selected (see supplementary figure 1).
PSG recordings and sleep measures
PSG recordings were continuously monitored and
recorded throughout an 8 h baseline sleep episode
using a Vitaport-3 recording system (TEMEC
Instruments, B.V. Kerkrade, The Netherlands).
Recordings included the EEG (derivations C3,
C4, O1 and O2, referenced to contralateral mas-
toids), right and left electrooculogram, electro-
myogram and the ECG. Electrode impedances
were <10 kΩ prior to the beginning of each
recording. EEG signals were filtered (high-pass
EEG filter 0.23 Hz; low-pass EEG filter 70.1 Hz;
24 dB/octave, sampling rate 256 Hz). PSG records
were scored (blind to genotype) visually in 30 s
epochs according to conventional criteria of
Rechtschaffen and Kales (1968). Sleep measures
included total sleep time (TST); sleep efficiency
(TST/time in bed as a %); sleep latency (interval
between lights off and first stage of sleep); duration
for stage 1, stage 2, and SWS (SWS; stages 3 and 4
combined), REM (rapid eye movement) sleep and
Figure 1. Raster plots of laboratory protocols show PSG recorded during 8 h sleep episodes for a representative participant with a
habitual sleep timing of 00:00–08:00. For all study protocols, the ambient room light was dim (gray) for at least 6 h before the sleep
episodes (black) during which PSGs were recorded. (a) In the phase 1 cohort, PSG was recorded (red box) during the third baseline
night. (b) The first baseline night was recorded in the phase 2 cohort.
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wakefulness; wake after sleep onset (WASO); wake
after final awakening (WAFA); and number of
awakenings longer than 30 s. Duration of sleep
stages and wakefulness was calculated in minutes.
For sleep stage 2, SWS and REM (rapid eye move-
ment) sleep, latencies were computed from sleep
onset. PSG measures that were not normally dis-
tributed were transformed to achieve a normal
distribution, including SWS duration and number
of awakenings (log transformation) and REM sleep
latency (inverse normal transformation).
Spectral analysis of C3/A2 EEG recordings was
also completed in the subset of male participants
whose PSG was recorded on the third baseline night
(n = 37; see below). Signals were first visually
inspected, and 4 s epochs containing artifacts aris-
ing from body movements, eye blinks or eye move-
ments were removed. The remaining 4 s epochs
were subjected to fast Fourier transformation,
using a 10%-cosine-tapered window (Vitascore,
TEMEC, The Netherlands). A maximum of 10 con-
secutive, overlapping 4 s epochs were averaged into
30 s epochs and matched with sleep scores. Data
were reduced further by averaging power densities
into 0.5 Hz bins. For a specific SNP that was asso-
ciated with SWS, power spectra were compared
between genotype groups (risk-allele carriers vs.
noncarriers) by ANOVA (SAS 9.2, SAS Institute
Inc., Cary, NC, USA).
Genetic analysis and protocol groups
Genetic analysis was initiated in a cohort in whom
PSG was recorded during the 8 h sleep episode on
the third baseline night (phase 1; n = 59; Figure 1a).
Potential associations with significance (p < 0.001)
were then tested in a separate cohort of different
individuals in whom PSG recordings were collected
during the 8 h sleep episode on the first baseline
night in the laboratory (phase 2; n = 25; Figure 1b).
Procedures for the collection of PSG, sleep sche-
dule, room conditions and ambient light levels
prior to the sleep episode were consistent between
phase 1 and 2 cohorts. Both groups were indepen-
dent with no overlap of individuals, and the cohorts
were selected a priori. The phase 2 group in which
PSG was collected during the first baseline night
was selected to provide a more stringent test of
replication for any potential associations that were
identified in the phase 1 cohort, assuming greater
variability in measures due to first-night effects.
An additive genetic model was used to test for
association of SNPs with sleep measures in linear
regression analyses. All analysis presented was
adjusted for covariates age, sex and ancestry (five
principal components). Permutation testing was
used to evaluate significance after correction for
multiple comparisons. As power for single-variant
association testing was low and individual effects
may be subtle, an additional gene-based analysis
was conducted using sequence kernel association
testing (SKAT) to detect combined effects of var-
iants (Ionita-Laza et al., 2013). This analysis pro-
vides a more comprehensive view of potential
associations between candidate genes and pheno-
types by including all variants from one gene, rather
than each individual SNP, in the analysis.
Furthermore, this allowed for a reduced number
of comparisons (the number of genes as opposed
to the number of SNPs).
Results
Summary sleep measures for both cohorts are shown
in Table 1. The cohorts differed significantly only in
REM sleep duration, with a shorter REM sleep dura-
tion in the phase 2 cohort, which may have been due
to a first-night effect in that cohort (Agnew et al.,
1966). Results for SNPs most strongly associated
with sleep phenotypemeasures in the phase 1 cohort,
in the phase 2 cohort and from meta-analysis of the
entire sample are listed in Table 2. In phase 1, an
SNP in the PER2 gene (rs6753456) showed a signifi-
cant association with SWS duration; a second PER2
SNP (rs3739064) was associated with the number of
awakenings; and a MTNR1B SNP (rs7942988) was
associated with REM sleep latency. None of these
associations remained significant in the smaller
phase 2 cohort in which only first-night sleep data
were assessed. Nonetheless, two associations
remained significant in the meta-analysis of both
phases of analysis: the PER2 SNP with SWS duration
and the MTNR1B SNP with REM sleep latency. For
the two phenotypes that showed significant associa-
tion in the meta-analysis, the association with all
tested SNPs is shown in supplementary figure 2;
and association plots for remaining sleep phenotypes
with all SNPs are shown in supplementary figure 3.
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Results from association testing of the two sleep-
associated SNPs with circadian phenotypes are
shown in supplementary table 2.
PER2
A common polymorphism in the PER2 gene
(rs6753456; MAF 38%) was significant in the
phase 1 sample for SWS duration with 24 min
less SWS in risk allele carriers compared to non-
carriers, a difference of 27% (p = 9.2 × 10−4;
Table 2). While the magnitude of the effect of
this PER2 SNP was similar in the phase 2 cohort
(19 min less of SWS), this association was not
statistically significant (p = 0.103). Meta-analysis
of both phases showed association with 20 min of
less SWS duration, equivalent to a 22% reduction
compared to noncarriers (p = 4.43 × 10−4). This
difference was significant after correction for mul-
tiple comparisons (padj = 0.046). Consistent results
of a study-wide significant association (p = 3.39 ×
10−4) with no heterogeneity of genetic effect
between the more controlled phase 1 cohort and
the noisier phase 2 cohort (I2 = 0%, phet = 0.49;
(Han & Eskin, 2011) were seen using a modified
random effect meta-analysis approach, indicating
Table 2. Genetic association results with PSG phenotypes.
Gene PER2 PER2 MTNR1B
SNP rs6753456 rs3739064 rs7942988
Minor allele G G T
Frequency (%) 37.5 21.3 3.7
PSG measure SWS duration (min) # awakenings/night REM latency (min)
Phase 1 cohort
n 59 57 57
β (SE) −24.37 (7.00) −9.64 (2.42) 81.19 (17.50)
β (SE)* −0.29 (0.08) −0.93 (0.25) 3.90 (1.00)
p* 9.2E-04 6.0E-04 3.1E-04
Phase 2 cohort
n 25 25 25
β (SE) −19.38 (10.41) −2.22 (4.51) 27.27 (27.66)
β (SE)* −0.19 (0.11) −0.02 (0.39) 1.47 (1.43)
p* 0.103 0.959 0.32
Meta-analysis
n 84 82 82
β (SE) −20.46 (5.58) −6.30 (2.23) 64.55 (14.46)
β (SE)* −0.24 (0.06) −0.54 (0.21) 0.61 (0.17)
p* 4.4E-04 1.3E-02 7.4E-04
padj* 4.6E-02 0.505 4.6E-02
Three SNPs (rs6753456, rs3739064 and rs7942988) showed association (p < 0.001) with PSG sleep phenotypes in the phase 1 cohort. The β and p
value of transformed data are denoted by asterisk. Adjusted p values (padj) were adjusted for multiple comparisons. Mean (SE) values for the
associated phenotypes are listed by genotype for each SNP for phase 1, phase 2 and meta-analysis of both cohorts; note these values are
unadjusted, while the betas are adjusted.
Table 1. Summary of sleep measures for phase 1 (n = 59) and phase 2 (n = 25) cohorts.
PSG measure Phase 1 mean (SD) Phase 2 mean (SD) t-Test p
TST (min) 440.98 (21.56) 431.76 (38.79) 0.272
Sleep efficiency (%) 91.85 (4.49) 89.92 (8.07) 0.269
Sleep latency (min) 10.59 (7.02) 12.26 (8.89) 0.410
Stage 1 duration (min) 26.17 (10.80) 21.38 (11.19) 0.077
Stage 2 duration (min) 209.90 (35.16) 219.18 (32.62) 0.250
Stage 2 latency (min) 3.54 (6.86) 4.46 (3.22) 0.407
SWS duration (min) 87.53 (34.74) 92.08 (28.99) 0.539
REM duration (min) 118.08 (23.52) 99.40 (20.96) 7.31E-04
REM latency (min) 73.28 (36.75) 80.02 (37.85) 0.456
WASO (min) 22.05 (20.44) 32.88 (34.49) 0.153
Awakenings >30 s 10.46 (6.92) 11.44 (8.43) 0.610
WAFA (min) 3.76 (14.02) 3.40 (7.68) 0.880
Significant p values (p < 0.05) are shown in bold.
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that the genetic signal was robust to differences
between the data sets. Model-estimated mean dif-
ferences ± SE for SWS duration for the phase 1,
phase 2, and meta-analysis groups are shown in
Figure 2a. Results from meta-analysis of both
phase groups revealed lower SWS in homozygous
and heterozygous groups compared to the nonrisk
allele carriers (Figure 2a).
EEG spectral analysis was carried out in the 37
male participants from the phase 1 sample in order
to eliminate heterogeneity by sex, given that SWS
power density differs between men and women
(Armitage, 1995; Dijk et al., 1989; Ehlers &
Kupfer, 1997) and because there was a very unequal
ratio of men to women in the genotype groups.
Genotype affected the power spectrum during
non-REM sleep in a frequency-specific manner
(genotype × EEG frequency bin, p = 0.049;
Figure 3a). Post hoc analysis showed that this effect
arose mainly from lower power density in the low
delta range (0.25–1.0 Hz; p < 0.044, F-test) in indi-
viduals with one or two copies of the risk allele
compared to noncarriers. Moreover, genotype
affected the time course of the typical SWA decline
across the night that is a measure of the decrease in
homeostatic sleep pressure across the night. The
biggest effects of genotype were observed in the
first half of the night, with lower EEG SWA in the
risk allele carriers and a shallower decline of SWA
across the sleep episode in the carriers (Figure 3b).
EEG power spectra during REM sleep were not
affected by genotype (data not shown).
Another common PER2 SNP (rs3739064; MAF
21.3%) showed notable association with the num-
ber of awakenings in the phase 1 cohort (p = 6.0 ×
10−4; Table 2). Minor allele homozygotes (G/G)
had an average of eight fewer awakenings per
night than either those with a single copy of the
minor allele (G/A) or noncarriers (A/A). This
association was not significant in the phase 2 sam-
ple and meta-analysis did not show significant
association after correction of multiple compari-
sons (p = 0.013, padj = 0.505).
MTNR1B
A SNP in the MTNR1B gene (rs7942988; MAF
3.7%) was significantly associated with REM sleep
latency from sleep onset (p = 3.10 × 10−4; Table 2)
in the phase 1 cohort. Individuals carrying the risk
allele showed much longer latencies to REM sleep
(by 81 min) than noncarriers, corresponding to a
doubling of REM sleep latency (111% increase).
This association was not significant in the phase 2
sample alone (p > 0.1), but significant (p = 4.14 ×
10−4, padj = 0.046; Table 2) in the overall sample,
with the latency from sleep onset to REM sleep 65
min (87%) longer in carriers than in noncarriers. In
a secondary meta-analysis assuming random effects
and testing for heterogeneity, this association
demonstrated a consistent effect between the
phase 1 and phase 2 cohorts (p = 6.5 × 10−3, I2 =
8.7%, phet = 0.30). The risk allele of rs7942988 (T) is
relatively rare with an MAF of 3.7% in our popula-
tion (6 T/C and 0 T/T individuals). The distribution
of REM sleep latency values from both the phase 1
and phase 2 cohorts are plotted in supplementary
figure 4 and show that half of the risk allele carriers
had REM sleep latencies that were more than twice
Figure 2. Model-estimated mean differences by genotype for
(a) PER2 SNP rs6753456 and SWS duration and (b) MTNR1B SNP
rs7942988 and REM sleep latency. Model-estimated means are
set to 0 min for each cohort and mean differences were
adjusted for covariates. Mean difference, standard error (SE)
and corresponding n for each genotype group are shown for
homozygous (black bars) and heterozygous (gray bars) carriers
for the risk allele and noncarriers (white bars).
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as long as the group average (>120 min). Post hoc
analysis found that genotype had a significant effect
on the chance of having an REM sleep latency >120
min using both χ2 analysis (OR = 8.79; CI = 1.48–
52.07; p = 0.008) and Fisher’s exact test (p = 0.015).
Figure 2b displays the model-estimated mean dif-
ferences for REM sleep latency in the phase 1 and
phase 2 cohorts by genotype.
This same MTNR1B gene variant rs7942988 that
associated with REM sleep latency had a significant
association (p = 0.013 with the duration of melatonin
secretion, calculated as the difference between the dim
light melatonin onset (DLMO) and offset (DLMOff).
Because melatonin was collected only in the phase 1
sample, there were only three individuals with this
rare allele (T) who had melatonin phase assessments
available, but they had a significantly reduced dura-
tion of nocturnal melatonin secretion by 1.33 h com-
pared to noncarriers, corresponding to a 13.1%
reduction (supplementary table 2). This association
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Figure 3. Effect of PER2 rs6753456 genotype on EEG power density during NREM sleep in the male subset (n = 37) of the phase 1
cohort. (a) Mean power density spectra (left: 0.25–25.0 Hz; right (enlarged): 0.25–3.0 Hz) are shown for risk allele carriers (filled
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with the melatonin secretion duration remained sig-
nificant after correcting for multiple testing of the
three SNPs (padj= 0.039). This SNPwas also associated
with an earlier diurnal preference (p = 0.041),
although this association was no longer significant
after correction for multiple testing of three SNPs.
Gene-based analysis
Results of SKAT gene-based analysis showed asso-
ciations for BHLHE41 (DEC2) with the duration of
REM sleep (p = 0.005), PER2 with SWS (p = 0.027)
and MTNR1B with REM sleep latency (p = 0.028)
in phase 1 cohort. Only the BHLHE41 association
remained significantly associated with REM sleep
duration after correcting for multiple comparisons
(five genes; padj = 0.01).
Discussion
Associations between single variants in two candi-
date genes and sleep PSG measures were identified
in our phase 1 sample. Meta analyses also showed
study-wide significant associations for PER2 SNP
rs6753456 with SWS duration and MTNR1B SNP
rs7942988 with REM sleep latency that withstood
correction for multiple tests. Neither association
was observed in the smaller phase 2 sample alone;
however, similar effect estimates and concordant
direction of the allelic effects were seen in both
samples. While statistical power ranged from 83%
to 89% (with α = 0.05) in the phase 2 sample to
replicate the effect that was observed in the phase
1 sample, lack of replication may be due to “win-
ner’s curse” in the initial sample, the small size of
the phase 2 sample, and/or less favorable/more
noisy experimental conditions during which the
PSG was recorded (first night in phase 2 cohort
versus third night in phase 1 cohort). As expected
for a “first-night” effect in the phase 2 cohort,
during which sleep is typically more disturbed
due to sleeping in an unfamiliar laboratory envir-
onment and PSG recordings for the first time,
there was significantly less REM sleep in the
phase 1 cohort (Agnew et al., 1966). First-night
effects in the phase 2 cohort therefore could have
confounded associations with the SNPs. Indeed,
we purposefully selected a “noisier” phase 2 cohort
to perform a stringent validation of significant
findings from the phase 1 cohort, reasoning that
replication despite the increased instability of first-
night measurements would favor true associations
over false positives. Replication in additional large
studies with EEG measurements will be important
to validate these associations. Our study identified
a common variant of PER2 (rs6753456) that was
significantly associated with decreased SWS dura-
tion in the combined analysis of both cohorts after
correction for multiple comparisons and showed a
large effect size (20 min reduction of SWS).
This SNP (rs6753456) is located in the upstream
promoter region of PER2, a core circadian clock
gene, and is in strong linkage disequilibrium (r2 =
0.8) in Europeans with rs11894491, a regulatory
variant annotated with promoter and enhancer his-
tone marks, DNAse hypersensitivity sites and poly-
merase II binding in multiple cell lines (Ward &
Kellis, 2012). However, these SNPs are uncorrelated
to another PER2 SNP in the 5’ untranslated region
that was reported to be associated with diurnal
preference (Carpen et al., 2005). In the current
study, PER2 gene variant rs6753456 was not asso-
ciated with diurnal preference or any other circa-
dian phenotype, such as timing of sleep, as was seen
with a rare PER2 missense mutation in a family
with advanced sleep phase disorder (Toh et al.,
2001). A study in mice showed that the effects of
an acute 6 h sleep deprivation on increasing PER2
expression were dependent on the time of day
(Curie et al., 2013). In that report, the authors
suggest that PER2 acts as an integrator of both
circadian and homeostatic signals. Our findings
are consistent with a role of PER2 in homeostatic
sleep regulation. First, the greatest genotype-depen-
dent differences in power density were found in the
low delta range of the non-REM sleep EEG, which
is particularly sensitive to changes in homeostatic
sleep pressure (Aeschbach et al., 1996). Second, the
differences in SWA were specifically seen during
the early part of sleep, that is, a time when homeo-
static sleep pressure and its manifestation in the
EEG are typically highest. To further corroborate
the potential role of circadian genes in homeostatic
sleep regulation, it will be important to subject
individuals with different genotypes to challenges
of the homeostatic system (e.g. sleep deprivation).
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The MTNR1B variant rs7942988 showed signifi-
cant association with REM sleep latency. The low
prevalence of this allele in our population may
explain the lack of replication. Although only 6/84
individuals were carriers for the risk allele, the effect
size was considerable (>1 h longer REM sleep
latency) and half of the carriers displayed REM
sleep latencies of more than 2 h (120 min), indicat-
ing a “skipped” first REM sleep episode. It is
remarkable that three of the six minor allele carriers
were in the small subgroup of nine individuals who
displayed a long REM sleep latency, consistent with
skipping the first REM sleep episode (see supple
mentary figure 4). Post hoc analysis to test whether
the chance for skipping of the first REM sleep
episode was significantly affected by the genotype
found a significant association using both χ2 analy-
sis and Fisher’s exact test. Since REM sleep is the
sleep state most influenced by circadian phase
(Czeisler et al., 1980) and MTNR1B is expressed
in the central circadian pacemaker, the suprachias-
matic nucleus (SCN) (Pandi-Perumal et al., 2008),
the association between an MTNR1B gene variant
and REM sleep latency may indicate that MTNR1B
function modulates the SCN control of REM sleep
propensity. This would need to be determined in
future studies. It is also notable that we observed a
significant association with a circadian phenotype
(1.33 h shorter duration of melatonin profile) and a
nominally significant association with diurnal pre-
ference (see supplementary table 2).
Although it is not clear how longer REM sleep
latency and shorter duration of melatonin secretion
are related, these findings suggest a possible role for
MTNR1B in the circadian regulation of sleep, speci-
fically REM sleep. Interestingly, and consistent with
such a potential relationship, REM sleep latency has
been reported to be increased in tetraplegia patients
with complete cervical spinal cord transection and
abolished nighttime peak in circulating melatonin
(Berlowitz et al., 2012; Scheer et al., 2006). More
recently, in a separate analysis, we have found that
the MTNR1B variant, rs10830963, previously asso-
ciated with increased fasting glucose levels and
increased risk of T2D is associated with longer dura-
tion of elevated melatonin levels and a delay in
circadian phase of melatonin offset in a similar inpa-
tient sample as the one in this analysis (Lane et al.,
2015). The variant in the current study, rs7942988, is
not itself associated with risk of T2D (http://dia
gram-consortium.org) or in strong linkage disequili-
brium with common or rareMTNR1B variants pre-
viously associated with T2D (Dupuis et al., 2010;
Lyssenko et al., 2008; Prokopenko et al., 2008).
Results of the gene-based analysis showed
trends of these associations for the PER2 and
MTNR1B variants with SWS duration and REM
sleep latency, respectively. In addition, the gene-
based analysis showed a significant association in a
third gene, BHLHE41, with REM sleep duration,
which was not identified by the analysis of indivi-
dual SNPs. A rare variant in this gene (also known
as DEC2) was associated with shorter sleep dura-
tion in humans (hDEC2-P385R) and less sleep
time in transgenic mice carrying this mutation as
compared to controls (He et al., 2009).
Furthermore, sleep deprivation studies of both
transgenic hDEC2-P385R mice and Dec2 knockout
mice showed slower recovery following sleep loss,
indicating the importance of this gene in sleep
regulation (He et al., 2009). We did not find this
rare variant in our entire sample, not surprising
given the very low frequency of this allele, and
thus were not able to replicate this previously
reported association. Taken together, however,
our findings support the evidence that BHLHE41
plays a role in the genetic regulation of sleep.
The small sample size was a limitation of this
study, and due to limited power in this sample, we
examined relatively common variants. A small sam-
ple size in addition to an unequal male/female ratio
in the genotype groups for PER2 SNP rs6753456 was
a limitation for the EEG spectral analysis. It will be
important to replicate these findings in large sam-
ples, especially for the rare MTNR1B variant. Given
the low number of minor allele carriers for this
variant (six) and the finding that three of these
showed significantly longer REM sleep latencies, it
is theoretically possible that skipping of the first
REM sleep episode could have influenced assessment
of SWS and SWA, measures of sleep homeostasis.
We found no direct association between MTNR1B
SNP rs7942988 and SWS, however, making it unli-
kely that carriers were under increased homeostatic
sleep pressure. Additionally, we focused our primary
analysis on a European subset of the sample in order
to examine a homogeneous group. Another limita-
tion was that we tested only a few candidate genes as
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opposed to a more comprehensive panel or GWAS,
although this reduced our multiple-testing burden.
Selection of candidate genes was partially based on
previously reported associations with circadian
rhythms (Toh et al., 2001), sleep phenotypes
(Allebrandt et al., 2010; He et al., 2009) and/or dia-
betes risk (Dupuis et al., 2010; Lyssenko et al., 2008;
Prokopenko et al., 2008); however, our aim was full
coverage of each candidate gene by tagged SNPs
rather than only previously associated SNPs.
Notably, we found associations with SNPs in two of
the five genes selected for this study. These positive
results are likely due to the use of the phenotypic
measures that were collected under exceedingly well-
controlled conditions in carefully screened partici-
pants and involved the application of consistent and
stringent procedures for the collection and analysis
of data across protocols. Further studies examining
these and other circadian gene variants with sleep
EEG collected under different conditions are needed
for replication of our results to determine functional
pathways and tissue specificity for gene expression
and for identification of other genetic associations.
Acknowledgements
We thank the study participants, the staff of the
Center for Clinical Investigation of the Brigham
and Women’s Hospital (BWH), for collection of
the genetic samples and the staff of the Broad
Institute, Cambridge, MA, for genotyping assays.
We also thank the BWH Sleep & EEG Core, in
particular Brandon Lockyer, for PSG analysis and
support; and Joseph Ronda for support with an
automated sleep summary program. We thank
Alana O’Malley, David Klements, Dayna
Bradstreet and the recruitment office of the
Division of Sleep Medicine for recruitment and
screening of study participants; and Shantha
Rajaratnam, Ph.D., and Melanie Rüger, Ph.D., for
their contributions to the study protocols.
Declaration of interest
This study was funded by National Institute of
Health (NIH) grant R21-DK089378, a pilot grant
from Harvard Catalyst, Harvard Clinical and
Translational Science Center (UL1 RR025758)
and financial contributions from Harvard
University. Additional funding was provided by
NIH grants HL080978, MH045130 and
HL077453; National Space Biomedical Research
Institute (NSBRI) grant HPF01601; the BWH
General Clinical Research Center (NIH M01-
02635); and a BWH Faculty Career Development
Award to AMC. AMC was supported in part by
NIH grant K01-HL115458. DA was supported in
part by the German Aerospace Center. SAS was
supported in part by NIH grant K24-HL076446.
FAJLS and RS were supported by a Harvard
Catalyst Pilot Grant, R21-DK089378, R01-
DK102696 and R21-HL121728. The content is
solely the responsibility of the authors and does
not necessarily represent the official views of the
NIH, Harvard Catalyst, Harvard University and its
affiliated academic healthcare centers, NSBRI or
BWH.
None of the authors have conflicts of interest
with the work presented but the following finan-
cial support is stated in the interest of full
disclosure.
Dr. Buxton reports research grant support from
the National Institutes of Health outside of the
submitted work; consulting with Matsutani
America (scientific advisory board) and Harvard
T.H. Chan School of Public Health. Travel support
and honoraria for speaking from American
Academy of Craniofacial Pain; Chevron; New
York University; Academy of Nutrition and
Dietetics; and Harvard T.H. Chan School of
Public Health. Dr. Buxton received two investiga-
tor-initiated grants from Sepracor Inc (now
Sunovion; ESRC-0004 and ESRC-0977,
ClinicalTrials.gov Identifiers NCT00555750,
NCT00900159), and two investigator-initiated
grants from Cephalon Inc (now Teva;
ClinicalTrials.gov Identifier: NCT00895570).
OMB received Speaker’s Bureau, CME and non-
CME lecture honoraria and an unrestricted educa-
tional grant from Takeda Pharmaceuticals North
America. OMB serves as a consultant and expert
witness for Dinsmore LLC, consulting fees for
serving on the Scientific Advisory Board of
Matsutani America, and consulting fees from the
Wake Forest University Medical Center (NC).
OMB received speaking fees and/or travel support
for speaking from American Academy of
Craniofacial Pain, NHLBI, NIDDK, National
570 A.-M. CHANG ET AL.
Postdoctoral Association, Oklahoma State
University, Oregon Health Sciences University,
SUNY Downstate Medical Center, American
Diabetes Association, and New York University.
Dr. Anderson has served as consultant to the Rail,
Bus and Tram Union. National Transport
Commission (Australia) and VicPolice. She has also
received research support from VicRoads and Sanofi-
Aventis, and has received lecturing fees from Brown
Medical School/Rhode Island Hospital and Ausmed.
Dr. Czeisler has received consulting fees from or
served as a paid member of scientific advisory boards
for: Bombardier, Inc.; Boston Bruins; Boston Celtics;
Boston Red Sox; Cephalon, Inc. (acquired by Teva
Pharmaceutical Industries Ltd. October 2011);
Koninklijke Philips Electronics, N.V. (acquired
Respironics, Inc. March 2008); Michael Jackson’s
mother and children; Novartis; Sleep Multimedia,
Inc.; United Parcel Service (UPS); Vanda
Pharmaceuticals, Inc.; and Zeo Inc. CAC owns an
equity interest in Apple; Lifetrac, Inc.; Microsoft;
Somnus Therapeutics, Inc.; Vanda Pharmaceuticals,
Inc., and Zeo Inc., and received royalties from
McGraw Hill, Penguin Press/Houghton Mifflin
Harcourt, and Philips Respironics, Inc. He has also
received research support from Cephalon, National
Football League Charities, ResMed and Philips
Respironics; and has received lecture fees from APSS
(Associated Professional Sleep Societies); AWHONN
(Association of Women’s Health, Obstetric and
Neonatal Nurses); Harvard School of Public Health;
Hokkaido University Graduate School of Medicine;
Japan Society for Occupational Health; Society of
Thoracic Surgeons; University of Washington; the
World Federation of Sleep Research and Sleep
Medicine Societies and WME Entertainment LLC.
CAC has also received research prizes with monetary
awards from the American Academy of Sleep
Medicine. The Harvard Medical School Division of
Sleep Medicine (HMS/DSM), which CAC directs, has
received unrestricted research and educational gifts
and endowment funds from: Boehringer Ingelheim
Pharmaceuticals, Inc., Cephalon, Inc., George H.
Kidder, Esq., Gerald McGinnis, GlaxoSmithKline,
Herbert Lee, Hypnion, Jazz Pharmaceuticals,
Jordan’s Furniture, Merck & Co., Inc., Peter C.
Farrell, Ph.D., Pfizer, ResMed, Respironics, Inc.,
Sanofi-Aventis, Inc., Sealy, Inc., Sepracor, Inc.,
Simmons, Sleep Health Centers LLC, Spring Aire,
Takeda Pharmaceuticals and Tempur-Pedic. The
HMS/DSM has received gifts from many outside
organizations and individuals including: Cephalon,
Inc., Committee for Interns and Residents, Eisai,
Inc., Farrell Family Foundation, Fisher & Paykel
Healthcare Corporation, Gerald McGinnis, Jazz
Pharmaceuticals, Jordan’s Furniture, Lilly USA, LLC,
Neurocare Center for Sleep, NeuroScience, Novartis
Consumer Health, Philips-Respironics, Inc., Praxair
US Homecare, Purdue Pharma, ResMed Foundation,
Safeway, Sanofi-Aventis, Inc., Select Comfort
Corporation, Sleep HealthCenters LLC, Somaxon
Pharmaceuticals, Transcept Pharmaceuticals, United
Healthcare, Vanda Pharmaceuticals, Inc., Wake Up
Narcolepsy, Inc., Watermark Medical, Weight
Watchers International, YMCA of the USA and Zeo,
Inc. The HMS/DSM Sleep and Health Education
Program has received Educational Grant funding
from Cephalon, Inc., Takeda Pharmaceuticals,
Sanofi-Aventis, Inc. and Sepracor, Inc. CAC is the
incumbent of an endowed professorship provided to
Harvard University by Cephalon, Inc. and holds a
number of process patents in the field of sleep/circa-
dian rhythms (e.g., photic resetting of the human
circadian pacemaker). Since 1985, CAC has also
served as an expert witness on various legal cases
related to sleep and/or circadian rhythms.
Dr. Lockley has received consulting fees from
Naturebright, Sound Oasis, Thomas Jefferson
University and Wyle Integrated Science and
Engineering (NASA), Blackrock, Cowen & Co,
Endurant Capital Management, Far West Capital
Management, Fidelity, Frankel Group, Impax
Laboratories, Kearney Venture Partners, Lazard
Capital Markets, New Horizon Capital, Perceptive
Advisors, Polar Capital, ResearchWorks Inc, and
Wyvern Funds. He has also received unrestricted
equipment gifts from Biological Illuminations LLC,
Bionetics Corporation, and Philips Lighting; an
unrestricted monetary gift from Swinburne
University of Technology, Australia; a fellowship gift
from Optalert, Pty, Melbourne, Australia; equity in
iSLEEP, Pty, Melbourne, Australia; and advance
author payment and royalties from Oxford
University Press and from Elsevier. SWL has received
honoraria and/or travel and accommodation support
from 8th International Conference on Managing
Fatigue; 14th Annual Tennessee Perfusion
Conference; Brown University; Connecticut Business
CHRONOBIOLOGY INTERNATIONAL 571
& Industry AssociationHealth and Safety Conference;
Emergency Services Steering Committee; Estee
Lauder; Harvard University; Lighting Science Group
Corp; Massachusetts General Hospital; MediCom
Worldwide, Inc (CME); Midwest Lighting Institute;
National Research Council Canada; New England
College of Occupational and Environmental
Medicine; Ontario Association of Fire Chiefs; Rio
Tinto; UMass Memorial; Woolcock Institute of
Medical Research; and Wyle Integrated Science and
Engineering. He has received investigator-initiated
research grants from Biological Illuminations LLC,
Philips Lighting, and Vanda Pharmaceuticals and
has served as a paid expert on behalf of six public
bodies in arbitration hearings related to sleep, circa-
dian rhythms and work hours in firefighters and
police.
References
Achermann P, Dijk DJ, Brunner DP, Borbély AA. (1993). A
model of human sleep homeostasis based on EEG slow-
wave activity: Quantitative comparison of data and simu-
lations. Brain Res Bull. 31:97–113.
Aeschbach D, Cajochen C, Landolt H-P, Borbély AA. (1996).
Homeostatic sleep regulation in habitual short sleepers and
long sleepers. Am J Physiol. 270:R41–R53.
Agnew HW, Jr., WebbWB,Williams RL. (1966). The first night
effect: An EEG study of sleep. Psychophysiol. 2:263–266.
Allebrandt KV, Teder-Laving M, Akyol M, et al. (2010).
CLOCK gene variants associate with sleep duration in two
independent populations. Biol Psychiatry. 67:1040–1047.
Ambrosius U, Lietzenmaier S, Wehrle R, et al. (2008).
Heritability of sleep electroencephalogram. Biol Psychiatry.
64:344–348.
Armitage R. (1995). The distribution of EEG frequencies in
REM and NREM sleep stages in healthy young adults.
Sleep. 18:334–341.
Bachmann V, Klein C, Bodenmann S, et al. (2012). The
BDNF Val66Met polymorphism modulates sleep intensity:
EEG frequency- and state-specificity. Sleep. 35:335–344.
Barrett JC, Fry B, Maller J, Daly MJ. (2005). Haploview:
Analysis and visualization of LD and haplotype maps.
Bioinformatics. 21:263–265.
Berlowitz DJ, Spong J, Gordon I, et al. (2012). Relationships
between objective sleep indices and symptoms in a com-
munity sample of people with tetraplegia. Arch Phys Med
Rehabil. 93:1246–1252.
Bodenmann S, Hohoff C, Freitag C, et al. (2012).
Polymorphisms of ADORA2A modulate psychomotor vig-
ilance and the effects of caffeine on neurobehavioural
performance and sleep EEG after sleep deprivation. Br J
Pharmacol. 165:1904–1913.
Bodenmann S, Landolt HP. (2010). Effects of modafinil on
the sleep EEG depend on Val158Met genotype of COMT.
Sleep. 33:1027–1035.
Bollen KA, Curran PJ. (2005). Latent growth curve models: A
structural equation perspective. Hoboken, NJ: Wiley.
Borbély AA. (1982). A two process model of sleep regulation.
Hum Neurobiol. 1:195–204.
Carpen JD, Archer SN, Skene DJ, et al. (2005). A single-
nucleotide polymorphism in the 5’-untranslated region of
the hPER2 gene is associated with diurnal preference. J
Sleep Res. 14:293–297.
Curie T, Mongrain V, Dorsaz S, et al. (2013). Homeostatic
and circadian contribution to EEG and molecular state
variables of sleep regulation. Sleep. 36:311–323.
Czeisler CA, Weitzman ED, Moore-Ede MC, et al. (1980).
Human sleep: Its duration and organization depend on its
circadian phase. Science. 210:1264–1267.
Dijk DJ, Beersma DGM, Bloem G. (1989). Sex differences in
the sleep EEG of young adults: Visual scoring and spectral
analysis. Sleep. 12:500–507.
Dupuis J, Langenberg C, Prokopenko I, et al. (2010). New
genetic loci implicated in fasting glucose homeostasis and
their impact on type 2 diabetes risk. Nat Genet. 42:105–116.
Ehlers CL, Kupfer DJ. (1997). Slow-wave sleep:Do young adult
men and women age differently? J Sleep Res. 6:211–215.
Guindalini C, Mazzotti DR, Castro LS, et al. (2014). Brain-
derived neurotrophic factor gene polymorphism predicts
interindividual variation in the sleep electroencephalo-
gram. Journal of neuroscience research. 92:1018–1023.
Han B, Eskin E. (2011). Random-effects model aimed at
discovering associations in meta-analysis of genome-wide
association studies. Am J Hum Genet. 88:586–598.
Hanlon EC, Van Cauter E. (2011). Quantification of sleep
behavior and of its impact on the cross-talk between the
brain and peripheral metabolism. Proceedings of the
National Academy of Sciences of the United States of
America. 108 Suppl 3:15609–15616.
He Y, Jones CR, Fujiki N, et al. (2009). The transcriptional
repressor DEC2 regulates sleep length in mammals.
Science. 325:866–870.
Ionita-Laza I, Lee S, Makarov V, et al. (2013). Sequence
kernel association tests for the combined effect of rare
and common variants. Am J Hum Genet. 92:841–853.
Landolt HP, Dijk D. (2010). Genetic basis of sleep in healthy
humans. In MH Kryger, Roth T, WC Dement (Eds).
Principles and Practice of Sleep Medicine. St. Louis, MO:
Elsevier Saunders, pp. 175–183.
Lane JM, Chang AM, Consortium C, et al. (2015). Impact of
common variation at diabetes trait loci MTNR1B and
CRY2 on sleep, circadian and melatonin physiology.
Sleep. 38:A5–6.
Lennox WG, Gibbs EL, Gibbs FA. (1945). The brain-wave pat-
tern, an hereditary trait. The Journal of Heredity. 36:233–243.
Linkowski P. (1999). EEG sleep patterns in twins. J Sleep Res.
8 Suppl 1:11–13.
Lyssenko V, Nagorny CL, Erdos MR, et al. (2008). Common
variant in MTNR1B associated with increased risk of type
572 A.-M. CHANG ET AL.
2 diabetes and impaired early insulin secretion. Nat Genet.
41:82–88.
Mignot E, Young T, Lin L, Finn L. (1999). Nocturnal sleep
and daytime sleepiness in normal subjects with HLA-
DQB1*0602. Sleep. 22:347–352.
Nedeltcheva AV, Scheer FA. (2014). Metabolic effects of sleep
disruption, links to obesity and diabetes. Curr Opin
Endocrinol Diabetes Obesity. 21:293–298.
Pandi-Perumal SR, Trakht I, et al. (2008). Physiological
effects of melatonin: Role of melatonin receptors and sig-
nal transduction pathways. Prog Neurobiol. 85:335–353.
Prokopenko I, Langenberg C, Florez JC,et al. (2008). Variants in
MTNR1B influence fasting glucose levels.NatGenet. 41:77–81.
Purcell S, Neale B, Todd-Brown K, et al. (2007). PLINK: A
tool set for whole-genome association and population-
based linkage analyses. Am J Hum Genet. 81:559–575.
Rechtschaffen A, Kales A. (1968). A manual of standardized
terminology, techniques and scoring system for sleep stages
of human Subjects. Washington, D.C.: US Government
Printing Office.
Retey JV, Adam M, Honegger E, et al. (2005). A functional
genetic variation of adenosine deaminase affects the
duration and intensity of deep sleep in humans. PNAS.
102:15676–15681.
Scheer FA, Zeitzer JM, Ayas NT, et al. (2006). Reduced sleep
efficiency in cervical spinal cord injury; association with
abolished night time melatonin secretion. Spinal Cord.
44:78–81.
Spiegel K, Knutson K, Leproult R, et al. (2005). Sleep loss: A
novel risk factor for insulin resistance and Type 2 diabetes.
J Appl Physiol. 99:2008–2019.
Toh KL, Jones CR, He Y, et al. (2001). An h Per2 phosphor-
ylation site mutation in familial advanced sleep-phase syn-
drome. Science. 291:1040–1043.
van Beijsterveldt CE, van Baal GC. (2002). Twin and family
studies of the human electroencephalogram: A review and
a meta-analysis. Biol Psychol. 61:111–138.
Viola AU, Archer SN, James LM, et al. (2007). PER3 poly-
morphism predicts sleep structure and waking perfor-
mance. Curr Biol. 17:1–6.
Ward LD, Kellis M. (2012). HaploReg: A resource for explor-
ing chromatin states, conservation, and regulatory motif
alterations within sets of genetically linked variants.
Nucleic Acids Res. 40:D930–934.
CHRONOBIOLOGY INTERNATIONAL 573
